Luotonin A
目录号 : GC15612
A cytotoxic alkaloid
Cas No.:205989-12-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 1.8 μg/mL for P-388 cell line
Luotonin A binds to and stabilizes the topoisomerase I-DNA binary complex.
Topoisomerase DNA complexes have been reported as the primary target of several important antitumor agents. These agents have been shown to be able to increase the number of topoisomerase-associated DNA strand breaks in cells, by stabilizing the covalent enzyme-DNA complex and therefore diminishing the resealing of the DNA phosphodiester linkages
In vitro: Luotonin A was isolated as a pyrroloquinazolinoquinoline alkaloid from the Chinese medicinal plant Peganum nigellastrum. Luotonin A could stabilize the human DNA topoisomerase I-DNA covalent binary complex and mediate topoisomerase I-dependent cytotoxicity in intact cells. Similar to camptothecin, luotonin A was able to effect concentration-dependent stabilization of the enzyme-DNA binary complex. However, neither camptothecin nor luotonin A had any measurable effect on DNA in the absence of topoisomerase I. In addition, luotonin A was evaluated in a strain of Saccharomyces cereVisiae lacking yeast topoisomerase I, but having a plasmid having the human topoisomerase I gene under the control of a galactose promoter. Results showed that luotonin A at 1 μM concentration could produce 36% inhibition of growth in the presence of galactose. Moreover, in replicate experiments, lutonin A exhibited IC50 values from 5.7 to 12.6 μM in the presence of galactose, while the comparable values for camptothecin were from 0.74 to 0.86 μM [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Cagir, A. ,Jones, S.H.,Gao, R., et al. Luotonin A. A naturally occurring human DNA topoisomerase I poison. Journal of the American Chemical Society 125(45), 13628-13629 (2003).
| Cas No. | 205989-12-4 | SDF | |
| 化学名 | quino[2',3':3,4]pyrrolo[2,1-b]quinazolin-11(13H)-one | ||
| Canonical SMILES | O=C1N2C(C(N=C(C=CC=C3)C3=C4)=C4C2)=NC5=CC=CC=C51 | ||
| 分子式 | C18H11N3O | 分子量 | 285.3 |
| 溶解度 | ≤3mg/ml in DMSO;3mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5051 mL | 17.5254 mL | 35.0508 mL |
| 5 mM | 0.701 mL | 3.5051 mL | 7.0102 mL |
| 10 mM | 0.3505 mL | 1.7525 mL | 3.5051 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。